GPT and familial primary hypomagnesemia: Across all dose levels, the most frequent TRAEs of any grade were corneal epitheliopathy (84.0%), blurred vision (74.1%), peripheral sensory neuropathy (53.1%), dry eyes (32.1%), muscular weakness (28.4%), anaemia (23.5%), increased blood creatine phosphokinase (22.2%), alopecia (22.2%), increased alanine aminotransferase (ALT) (18.5%), increased aspartate aminotransferase (AST) (18.5%), increased myoglobin blood (17.3%), hyponatremia (16.0%), and hypomagnesemia (16.0%) (Table 2).